Results 111 to 120 of about 3,608,670 (316)

Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study [PDF]

, 2014
BACKGROUND: Inflammatory bowel disease (IBD) starting during childhood has been assumed to impair quality of life (QoL) of affected children. As this aspect is crucial for further personality development, the health-related quality of life (HRQOL) was ...
Spalinger, J., Heyland, Klaas, Rogler, Gerhard, Schibli, S., Braegger, C.P., Koller, R., Pittet, Valérie, Schäppi, Michela, Rueger, V., Koller, Rebekka, Rogler, G., Herzog, Denise, Bühr, P., Herzog, D., Bühr, Patrick, Friedt, Michael, Friedt, M., Rueger, Vanessa, Braegger, Christian P, Schibli, Susanne, Nydegger, Andreas, Rogler, Daniela, Nydegger, A., Pittet, V., Spalinger, Johannes, Fournier, N., Schäppi, M., Fournier, Nicolas, Rogler, D., Heyland, K.   +29 more
core   +1 more source

The human gut microbiome across the life course

FEBS Letters, EarlyView.
Despite significant individual variation and continuous change throughout life, the human gut microbiome follows some life stage‐specific trends. This article provides a brief overview of how gut microbiome composition shifts across different phases of life. Created in BioRender. Özkurt, E. (2026) https://BioRender.com/8q4nrnc.
Alise J. Ponsero, Basak Bahcivanci, Antonietta Hayhoe, Animesh Acharjee, Ezgi Özkurt   +4 more
wiley   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study [PDF]

, 2017
BACKGROUND Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management.
Safroneeva, Ekaterina, Alex Straumann, Safroneeva, E., Thomas Greuter, Nicolas Fournier, Greuter, T., Gantenbein, C., Greuter, Thomas, Zeitz, J., Marijana Protic, Christine N. Manser, Martin Gubler, Heinrich, H., Juillerat, Pascal, Misselwitz, B., Spoerri, M., Raja Ali, R.A., Biedermann, L., Alain M. Schoepfer, Spoerri, Muriel, Froehlich, Florian, Fournier, N., Ekaterina Safroneeva, Fournier, Nicolas, Gerhard Rogler, Seibold, Frank, Froehlich, F., Scharl, Michael, Zeitz, Jonas, Michetti, P., Manser, C.N., Gantenbein, Claudine, Straumann, A., Pierre Michetti, Vavricka, Stephan R, Protic, M., Seibold, F., Rogler, Gerhard, Juillerat, P., Rogler, G., Manser, Christine N, Luc Biedermann, Benjamin Misselwitz, Vavricka, S.R., Frank Seibold, Scharl, M., Gubler, Martin, Michetti, Pierre, Stephan R. Vavricka, Gubler, M., Swiss IBD Cohort Study Group, Biedermann, Luc, Schoepfer, Alain M, Claudine Gantenbein, Misselwitz, Benjamin, Heinrich, Henriette, Straumann, Alex, Pascal Juillerat, Protic, Marijana, Jonas Zeitz, Florian Froehlich, Raja Affendi Raja Ali, Schoepfer, A.M., Henriette Heinrich, Raja Ali, Raja Affendi, Muriel Spoerri, Michael Scharl, Study Group, Swiss IBD Cohort   +67 more
core   +2 more sources

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Characteristics of foreign-born persons in the swiss hepatitis C cohort study: implications for screening recommendations [PDF]

, 2016
BACKGROUND: Switzerland recommends individuals who originate from high-prevalence countries to be screened for hepatitis C virus (HCV) infection. However, not all these persons are equally at risk. We thus aimed to describe the number and characteristics
Olivia Keiser, Negro, F., Fabio Giudici, Moriggia, A., Keiser, O., Barbara Bertisch (3167913), Janne Estill (378310), Estill, J., Moriggia, Alberto, Moradpour, Darius, Giudici, Fabio, Darius Moradpour (15815), Bertisch, B., Alberto Moriggia (3167910), Müllhaupt, Beat, Barbara Bertisch, Estill, Janne Anton Markus, Keiser, Olivia, Moradpour, D., Bertisch, Barbara, Negro, Francesco, Beat Müllhaupt, Janne Estill, Fabio Giudici (3167907), Swiss Hepatitis C Cohort Study, Francesco Negro, Francesco Negro (205592), Olivia Keiser (93991), Beat Müllhaupt (416436), Alberto Moriggia, Darius Moradpour, Giudici, F., Estill, Janne, Müllhaupt, B.   +33 more
core   +2 more sources

Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors [PDF]

, 2020
Background: Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and co-medications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey.
Battegay, Manuel, Berenguer, J, Young, J., Khoo, Saye, Berenguer, Juan, Marzolini, C., Swiss HIV Cohort Study,, Marzolini, C, Cavassini, M, Battegay, M., Lopez-Centeno, B, Berenguer, J., Khoo, S, Bucher, Heiner C, Calmy, Alexandra, Cipriani, Michela, Jaeckel, S, Calmy, A, Braun, Dominique L, Swiss HIV Cohort Study, Elzi, L, Study, Swiss HIV Cohort, Marzolini, Catia, Scherrer, A, Bucher, HC, Moffa, G, Scherrer, Alexandra U, Elzi, Luigia, Jaeckel, S., Jaeckel, Steffen, Lopez-Centeno, Beatriz, Bucher, Heiner C., Hachfeld, A, Gibbons, Sara, Moffa, G., Battegay, M, Calmy, A., Gibbons, S., Lopez-Centeno, B., Deutschmann, E, Scherrer, Alexandra U., Cavassini, M., McAllister, K, Elzi, L., Young, James, Khoo, S., Deutschmann, Elisabeth, Young, J, Gibbons, S, Cipriani, M., Hachfeld, Anna, Braun, Dominique L., Deutschmann, E., McAllister, Katie, Braun, D.L., Moffa, Giusi, Scherrer, A.U., McAllister, K., Bucher, H.C., Hachfeld, A., Braun, D, Cipriani, M, Cavassini, Matthias   +62 more
core   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source